Literature DB >> 11904740

High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.

A F Pelz1, H Kröning, A Franke, P Wieacker, M Stumm.   

Abstract

The BCR/ABL1 fusion gene is mainly caused by the t(9; 22)(q34; q11.2) translocation, which results in the Philadelphia (Ph) chromosome. The Ph chromosome is the typical hallmark in chronic myeloid leukemia (CML), but can also be present in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The BCR/ABL1 rearrangement is an important tumor classification marker and a useful prognostic factor allowing an adequate therapy management. Ph chromosome detection by conventional cytogenetics (CC) can be hampered by low quantity and quality of metaphases from tumor cells. Furthermore, BCR/ABL1 rearrangements may be hidden due to cryptic rearrangements or complex aberrations. Therefore, molecular cytogenetic methods turned out to be useful tools for the detection of BCR/ABL1 rearrangements. We performed fluorescent in situ hybridization (FISH) with the recently developed BCR/ABL1 D-FISH probe (QBIOgene, Illkirch, F) on cultured bone marrow and peripheral blood cells of 71 patients with CML, ALL, AML, and myeloproliferative disorder (MPD). FISH results and the results of banding methods were directly compared. Based on the analyses of >200 nuclei per patient, D-FISH correlated closely with CC and allowed an accurate quantification of BCR/ABL1 rearrangements even in a low percentage of aberrant cells. No false-positive or false-negative results were obtained. Furthermore, the D-FISH probe detected three cryptic and one complex BCR/ABL1 rearrangement, which were not visible by CC. We conclude that D-FISH reliably detects standard Ph chromosomes as well as its variant translocations and accurately quantifies BCR/ABL1 rearrangements prior and during cancer treatment as well as in the phase of remission, in daily routine tumor cytogenetic diagnostics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904740     DOI: 10.1007/s00277-001-0424-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.

Authors:  V Mühlbacher; T Haferlach; W Kern; M Zenger; S Schnittger; C Haferlach
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

3.  Evaluation of the Cepheid GeneXpert BCR-ABL assay.

Authors:  Zsolt Jobbagy; Reuel van Atta; Kathleen M Murphy; James R Eshleman; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells.

Authors:  Jin Cai; Yu Han; Hongmei Ren; Caiyu Chen; Duofen He; Lin Zhou; Gilbert M Eisner; Laureano D Asico; Pedro A Jose; Chunyu Zeng
Journal:  J Mol Cell Biol       Date:  2013-04-11       Impact factor: 6.216

5.  Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States.

Authors:  David Rizzieri; Joseph O Moore
Journal:  P T       Date:  2012-11

6.  Reliability Evaluation of Fluorescence In Situ Hybridization (FISH) and G-Banding on Bone Marrow and Peripheral Blood Cells in Chronic Myelogenous Leukemia Patients.

Authors:  Soheila Manaflouyan Khajehmarjany; Seyed Ali Rahmani; Seyed Hadi Chavoshi; Ali Esfahani; Ali Akbar Movassaghpour Akbari
Journal:  Cell J       Date:  2015-04-08       Impact factor: 2.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.